4′-Chlorodiazepam, a translocator protein (18 kDa) antagonist, improves cardiac functional recovery during postischemia reperfusion in rats

Experimental Biology and Medicine

Volumn 235, Issue 4, 2010, Pages 478-486

  Xiao, Junjie ^a,b   Liang, Dandan ^b   Zhang, Hong ^a,b   Liu, Ying ^a,b   Li, Fajie ^b   Chen, Yi Han ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

4 chlorodiazepam; Mitochondrial permeability transition pore; Oxidative enzyme; Postischemia reperfusion; Reactive oxygen species; Translocator protein (18 kDa)

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4' CHLORODIAZEPAM; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; UBIQUINOL CYTOCHROME C REDUCTASE; XANTHINE OXIDASE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4'-CHLORODIAZEPAM; ANTILIPEMIC AGENT; BENZODIAZEPINE DERIVATIVE; BZRP PROTEIN, RAT; CARRIER PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORONARY ARTERY BLOOD FLOW; DISEASE SEVERITY; ELECTRON TRANSPORT; ENZYME ACTIVITY; FLUOROMETRY; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART MITOCHONDRION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; MALE; MOLECULAR WEIGHT; NONHUMAN; RAT; REPERFUSION INJURY; SPECTROPHOTOMETRY; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HEART; HEART MUSCLE; HEMODYNAMICS; HUMAN; METABOLISM; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; ANTILIPEMIC AGENTS; BENZODIAZEPINONES; CARRIER PROTEINS; HEART; HEMODYNAMICS; HUMANS; MALE; MITOCHONDRIA, HEART; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTORS, GABA-A; RECOVERY OF FUNCTION;

EID: 77951646609     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2009.009291     Document Type: Article

References (40)

1. Ussher JR, Lopaschuk GD. The malonyl CoA axis as a potential target for treating ischaemic heart disease. Cardiovasc Res 2008;79:259-268
2. Suleiman MS, Halestrap AP, Griffiths EJ. Mitochondria: a target for myocardial protection. Pharmacol Ther 2001;89:29-46
3. Bolli R, Becker L, Gross G, Mentzer RJ, Balshaw D, Lathrop DA. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004;95:125-134 (Pubitemid 38988678)
4. Gustafsson AB, Gottlieb RA. Heart mitochondria: gates of life and death. Cardiovasc Res 2008;77:334-343
5. Szewczyk A, Wojtczak L. Mitochondria as a pharmacological target. Pharmacol Rev 2002;54:101-127
6. Di Lisa F, Bernardi P. Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole. Cardiovasc Res 2006;70:191-199
7. Veenman L, Gavish M. The peripheral-type benzodiazepine receptor and the cardiovascular system: implications for drug development. Pharmacol Ther 2006;110:503-524
8. Gavish M, Bachman I, Shoukrun R, Katz Y, Veenman L, Weisinger G, Weizman A. Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev 1999;51:629-650
9. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR, Gavish M. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006;27:402-409 (Pubitemid 44069585)
10. Leung AW, Halestrap AP. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim Biophys Acta 2008;1777:946-952
11. Javadov S, Karmazyn M, Escobales N. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J Pharmacol Exp Ther 2009;330:670-678
12. Zorov DB, Juhaszova M, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovasc Res 2009;83:213-225
13. Leducq N, Bono F, Sulpice T, Vin V, Janiak P, Fur GL, O'Connor SE, Herbert JM. Role of peripheral benzodiazepine receptors in mitochondrial, cellular, and cardiac damage induced by oxidative stress and ischemia-reperfusion. J Pharmacol Exp Ther 2003;306:828-837
14. Akar FG, Aon MA, Tomaselli GF, O'Rourke B. The mitochondrial origin of postischemic arrhythmias. J Clin Invest 2005;115:3527-3535
15. Brown DA, Aon MA, Akar FG, Liu T, Sorarrain N, O'Rourke B. Effects of 4′-chlorodiazepam on cellular excitation-contraction coupling and ischaemia-reperfusion injury in rabbit heart. Cardiovasc Res 2008;79:141-149 (Pubitemid 351881926)
16. Li J, Xiao J, Liu Y, Zhang G, Zhang H, Liang D, Liu Y, Zhang Y, Hu Y, Yu Z, Yan B, Jiang B, Peng L, Zhou ZN, Chen YH. Mitochondrial benzodiazepine receptors mediate cardioprotection of estrogen against ischemic ventricular fibrillation. Pharmacol Res 2009;60:61-67
17. Thandroyen FT, McCarthy J, Burton KP, Opie LH. Ryanodine and caffeine prevent ventricular arrhythmias during acute myocardial ischemia and reperfusion in rat heart. Circ Res 1988;62:306-314 (Pubitemid 18041952)
18. Walker MJA, Curtis MJ, Hearse DJ, Campbell RWF, Janse MJ, Yellon DM, Cobbe SM, Coker SJ, Harness JB, Harron DWG, Higgins AJ, Julian DG, Lab MJ, Manning AS, Northover BJ, Parratt JR, Riemersma RA, Riva E, Russell DC, Sheridan DJ, Winslow E, Woodward B. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia, infarction, and reperfusion. Cardiovasc Res 1988;22:447-455
19. Yang CS, Tsai PJ, Chou ST, Niu YL, Lai JS, Kuo JS. The roles of reactive oxygen species and endogenous opioid peptides in ischemia-induced arrhythmia of isolated rat hearts. Free Radic Biol Med 1995;18:593-598
20. Garcia-Rivas Gde J, Carvajal K, Correa F, Zazueta C. Ru360, a specific mitochondrial calcium uptake inhibitor, improves cardiac post-ischaemic functional recovery in rats in vivo. Br J Pharmacol 2006;149:829-837 (Pubitemid 44851707)
21. Halestrap AP, Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta 2009;1787:1402-1415
22. Khaliulin I, Clarke SJ, Lin H, Parker J, Suleiman MS, Halestrap AP. Temperature preconditioning of isolated rat hearts - a potent cardioprotective mechanism involving a reduction in oxidative stress and inhibition of the mitochondrial permeability transition pore. J Physiol 2007;581:1147-1161 (Pubitemid 46887984)
23. Baines CP. The mitochondrial permeability transition pore and ischemia-reperfusion injury. Basic Res Cardiol 2009;104:181-188
24. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion - a target for cardioprotection. Cardiovasc Res 2004;61:372-385 (Pubitemid 38210145)
25. Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 2003;549:513-524 (Pubitemid 36701762)
26. Obame FN, Zini R, Souktani R, Berdeaux A, Morin D. Peripheral benzodiazepine receptor-induced myocardial protection is mediated by inhibition of mitochondrial membrane permeabilization. J Pharmacol Exp Ther 2007;323:336-345 (Pubitemid 47443246)
27. Townsend PA, Davidson SM, Clarke SJ, Khaliulin I, Carroll CJ, Scarabelli TM, Knight RA, Stephanou A, Latchman DS, Halestrap AP. Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress. Am J Physiol Heart Circ Physiol 2007;293:H928-38
28. Chanoit G, Lee S, Xi J, Zhu M, McIntosh RA, Mueller RA, Norfleet EA, Xu Z. Exogenous zinc protects cardiac cells from reperfusion injury by targeting mitochondrial permeability transition pore through inactivation of glycogen synthase kinase-3beta. Am J Physiol Heart Circ Physiol 2008;295:H1227-33
29. Clarke SJ, McStay GP, Halestrap AP. Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J Biol Chem 2002;277:34793-34799
30. Weiss JN, Korge P, Honda HM, Ping P. Role of the mitochondrial permeability transition in myocardial disease. Circ Res 2003;93:292-301
31. 2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2006;290:H2024-34
32. 2+ overload and ROS release. Cardiovasc Res 2008;77:406-415
33. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 2004;61:461-470
34. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003;108:1912-1916
35. Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol 2008;4:278-286
36. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005;115:500-508
37. Paradies G, Petrosillo G, Pistolese M, Di Venosa N, Federici A, Ruggiero FM. Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart: involvement of reactive oxygen species and cardiolipin. Circ Res 2004;94:53-59
38. Petrosillo G, Ruggiero FM, Di Venosa N, Paradies G. Decreased complex III activity in mitochondria isolated from rat heart subjected to ischemia and reperfusion: role of reactive oxygen species and cardiolipin. FASEB J 2003;17:714-716
39. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 2002;282:C227-41
40. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 2006;71:208-215